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Summary
 
Asthma exacerbations, many of which are virus induced, are associated with airway eosino-
philia. This may reflect altered inflammatory response to viruses in atopic individuals. Inhibi-
tory M
 
2
 
 muscarinic receptors (M
 
2
 
Rs) on the airway parasympathetic nerves limit acetylcholine
release. Both viral infection and inhalational antigen challenge cause M
 
2
 
R dysfunction, leading
to airway hyperresponsiveness. In antigen-challenged, but not virus-infected guinea pigs, M
 
2
 
R
dysfunction is due to blockade of the receptors by the endogenous antagonist eosinophil major
basic protein (MBP). We hypothesized that sensitization to a nonviral antigen before viral in-
fection alters the inflammatory response to viral infection, so that M
 
2
 
R dysfunction and hyper-
reactivity are eosinophil mediated. Guinea pigs were sensitized to ovalbumin intraperitoneally,
and 3 wk later were infected with parainfluenza. In sensitized, but not in nonsensitized animals,
virus-induced hyperresponsiveness and M
 
2
 
R dysfunction were blocked by depletion of eosino-
phils with antibody to interleukin (IL)-5 or treatment with antibody to MBP. An additional
and unexpected finding was that sensitization to ovalbumin caused a marked (80%) reduction
in the viral content of the lungs. This was reversed by the antibody to IL-5, implicating a role
for eosinophils in viral immunity.
Key words: eosinophils • muscarinic receptors • parainﬂuenza virus • antigen challenge •
viral immunity
 
V
 
iruses are a significant cause of asthma exacerbations
in adults and children (1). Although a variety of
mechanisms may contribute to virus-induced asthma exac-
erbation, it is known that the neural control of the airways
is markedly abnormal during viral infection. In normal
subjects, viral infection causes airway hyperresponsive-
ness that is vagally mediated and is blocked by anticho-
linergics (2).
In the lungs, parasympathetic nerves provide the domi-
nant autonomic control of airway smooth muscle (3). Re-
lease of acetylcholine onto M
 
3
 
 muscarinic receptors located
on the airway smooth muscle causes bronchoconstriction
(4). Under normal physiological conditions, release of ace-
tylcholine from parasympathetic nerves is inhibited by
prejunctional M
 
2
 
 muscarinic receptors (M
 
2
 
Rs)
 
1
 
 on the
nerves (5). Stimulation of these receptors with acetylcho-
line or with muscarinic agonists such as pilocarpine de-
creases vagally induced bronchoconstriction via inhibition
of acetylcholine release (5). Conversely, loss of M
 
2
 
R function
or blockade of these neuronal receptors with antagonists
leads to increased release of acetylcholine and increased va-
gally induced bronchoconstriction (6).
In antigen-challenged guinea pigs, hyperresponsiveness is
due to loss of neuronal M
 
2
 
R function. Loss of M
 
2
 
R func-
tion is mediated by eosinophils, since depletion of eosino-
phils (7) or inhibition of eosinophil migration into the
lungs (6) prevents loss of M
 
2
 
R function. Eosinophils release
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2
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2
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P
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, pul-
monary inflation pressure; RSV, respiratory syncytial virus; TCID
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50
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major basic protein (MBP), which is an endogenous allo-
steric antagonist for M
 
2
 
Rs (8). Heparin, which binds MBP,
acutely restores M
 
2
 
R function and rapidly reverses airway
hyperreactivity in antigen-challenged animals (9). In addi-
tion, an antibody to guinea pig eosinophil MBP (AbMBP)
prevents M
 
2
 
R dysfunction and associated hyperreactivity,
demonstrating that it is eosinophil MBP that is blocking
neuronal M
 
2
 
Rs and causing hyperreactivity in antigen-
challenged guinea pigs (10).
In contrast, virus-induced loss of M
 
2
 
R function is not
mediated by eosinophils. Eosinophils are not typically in-
creased in the bronchoalveolar lavage of virus-infected ani-
mals. Furthermore, heparin, which restores M
 
2
 
R function
in antigen-challenged guinea pigs, has no effect in virus-
infected guinea pigs (11).
In animals sensitized to a nonviral protein before viral in-
fection, the inflammatory response to viral infection is
switched to involve eosinophils. Coyle et al. have shown
that, in mice, virus-specific CD8
 
1
 
 T cells respond to viral
protein by generating IL-2 and INF-
 
g
 
, leading to an influx
of neutrophils and mononuclear cells into the airways (12).
In contrast, virus-specific CD8
 
1
 
 T cells from animals sensi-
tized to a nonviral protein, OVA, release large amounts of
IL-4 and IL-5 in response to the same viral stimulus. In
vivo, sensitization of mice leads to an eosinophilic response
to viral antigen in the lung.
Since many asthmatics are atopic, their inflammatory re-
sponse after viral infection might be altered in a similar
manner. The experiments described in this paper were de-
signed to test whether eosinophils and eosinophil MBP are
responsible for virus-induced hyperreactivity and loss of
M
 
2
 
R function in animals sensitized to OVA, but not subse-
quently challenged with OVA inhalation.
 
Materials and Methods
 
Animals.
 
Specific pathogen-free female Dunkin-Hartley guinea
pigs (180–300 g; Hilltop Lab Animals) were used. All animals
were shipped in filtered crates and kept in high-efficiency particu-
late-filtered air. Guinea pigs were fed a normal diet (Prolab; Ag-
way) and were handled in accordance with the standards established
by the United States Animal Welfare Acts set forth in National In-
stitutes of Health guidelines and the “Policy and Procedures
Manual” published by the Johns Hopkins University School of
Hygiene and Public Health Animal Care and Use Committee.
 
Study Protocol.
 
Animals were sensitized to OVA by intraperi-
toneal injection on days 1, 3, and 5 (see sensitization below). 3 wk
later, animals were exposed to either parainfluenza virus or con-
trol medium via nasal instillation (see viral infection below).
Some animals were treated with AbMBPs on the day of infection
and 2 d later. Another group of animals was treated with anti-
body to IL-5 (AbIL5), 5 and 3 d before infection. All studies of
airway function, inflammatory responses, and lung viral content
were done 4 d after infection.
 
Sensitization.
 
Pathogen-free guinea pigs were sensitized to
OVA. Animals were injected intraperitoneally with 10 mg
 
?
 
kg
 
2
 
1
 
OVA (0.3 ml) every other day for a total of three injections.
Nonsensitized, pathogen-free guinea pigs were used as controls.
Sensitization to OVA was confirmed 21 d later by intravenously
injecting 1.0 ml of 2.5% OVA randomly into a few animals from
each group. This dose caused acute, lethal anaphylaxis in all
groups of sensitized guinea pigs, but had no effect in nonsensi-
tized guinea pigs.
 
Viral Infection.
 
Parainfluenza type 1 (Sendai virus, VR-105;
American Type Culture Collection) was grown in rhesus mon-
key kidney cell monolayers in L-15 medium for 1 wk at 34
 
8
 
C.
Cells and medium were frozen and thawed, cleared by low-speed
centrifugation, and stored in aliquots at 
 
2
 
70
 
8
 
C. Animals were
anesthetized intramuscularly with ketamine (30 mg
 
?
 
kg
 
2
 
1
 
) and xy-
lazine (5 mg
 
?
 
kg
 
2
 
1
 
), and were inoculated intranasally with 0.5 ml
of virus stock diluted in Hank’s PBS to produce a solution con-
taining a 10
 
5
 
 tissue culture ID
 
50
 
 (TCID
 
50
 
) ml
 
2
 
1
 
 (10
 
5
 
 times the
concentration required to produce infection in 50% of rhesus
monkey kidney monolayers). Infected and noninfected animals
were housed in separate laminar flow rooms.
 
Pretreatments.
 
Some animals from both the sensitized virus-
infected and nonsensitized virus-infected groups were given 240
 
m
 
l
 
?
 
kg
 
2
 
1
 
 of AbIL5 intraperitoneally 3 and 5 d before infection.
Some of the sensitized virus-infected guinea pigs were pretreated
intraperitoneally with AbMBP (13) 1.5 ml immediately before
infection, and again 2 d after infection.
 
Measurements of Pulmonary Inflation Pressure.
 
Experiments were
conducted 4 d after viral infection. The guinea pigs were anes-
thetized intraperitoneally with urethane (1.5 g
 
?
 
kg
 
2
 
1
 
). This dose
produces a deep anesthesia lasting 8–10 h, although none of these
Figure 1. Pilocarpine (1–100 mg?kg21 intravenous) inhibits vagally in-
duced bronchoconstriction in pathogen-free guinea pigs, whether they
are sensitized (open circles, n 5 7) or not (open squares, n 5 8). In con-
trast, pilocarpine does not inhibit vagally induced bronchoconstriction in
virus-infected animals, whether they are sensitized (filled circles, n 5 10)
or not (filled squares, n 5 7). Results are expressed as the ratio of vagally
induced bronchoconstriction in the presence of pilocarpine to the re-
sponse of vagal stimulation in the absence of pilocarpine. There was a sig-
nificant difference between the pilocarpine dose–response curves in non-
infected versus virus-infected guinea pigs (P , 0.0001). Each point is the
mean, with SEM shown by vertical bars. 
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experiments lasted longer than 4 h. Both jugular veins were can-
nulated for the administration of drugs. One internal carotid ar-
tery was cannulated for measurement of blood pressure using a
DTX™ pressure transducer (Viggo-Spectramed), and the heart
rate was derived from the blood pressure tracing using a tacho-
graph. The trachea was cannulated, and the animals were venti-
lated with a positive pressure, constant volume rodent respirator
(Harvard Apparatus, Inc.) at a tidal volume of 10 ml
 
?
 
kg
 
2
 
1
 
 and a
respiratory rate of 100 breaths
 
?
 
min
 
2
 
1
 
. The animals were paralyzed
by intravenously infusing succinylcholine (10 
 
m
 
g
 
?
 
kg
 
2
 
1
 
?
 
min
 
2
 
1
 
).
All animals were pretreated intraperitoneally with guanethidine
(10 mg
 
?
 
kg
 
2
 
1
 
) to deplete norepinephrine. Pulmonary inflation
pressure (
 
P
 
pi
 
) was measured at the trachea using a DTX™ pres-
sure transducer. All signals were recorded on a polygraph (Grass
Instrument Co.). Bronchoconstriction was measured as the in-
crease in 
 
P
 
pi
 
 above the basal inflation pressure produced by the
ventilator. The sensitivity of the method was increased by taking
the output 
 
P
 
pi
 
 signal from the driver of one channel to the input
of the preamplifier of a different channel on the polygraph. Thus,
baseline 
 
P
 
pi
 
 was recorded on one channel and increases in 
 
P
 
pi
 
above the baseline were recorded on a separate channel. With
this method, increases in 
 
P
 
pi
 
 as small as 2–3 mm H
 
2
 
O can be ac-
curately recorded.
 
Studies of Vagal Hyperresponsiveness.
 
Both vagus nerves were
cut, and the distal ends were placed on shielded electrodes im-
mersed in liquid paraffin. Electrical stimulation of both vagus
nerves produced bronchoconstriction and bradycardia. The vagus
nerves were stimulated at frequencies ranging 2.0–25.0 Hz for 5 s
at 120-s intervals, keeping both pulse duration (0.1 ms) and volt-
age (10.0 V) constant between groups. At the end of each exper-
iment, heparin (2,000 U) was given intravenously to both sensi-
tized virus-infected and nonsensitized virus-infected animals.
After 15–20 min, the response to vagal stimulation was remea-
sured as above. After the completion of each experiment, atro-
pine (1 mg
 
?
 
kg
 
2
 
1
 
) was administered intravenously to confirm that
bronchoconstrictions were due to cholinergic nerve stimulation.
Changes in 
 
P
 
pi
 
 were recorded on a Grass polygraph as described
above.
 
Studies of Neuronal M
 
2
 
R Function.
 
30 min after administering
guanethidine, baseline responses to electrical stimulation of the
vagus nerves were obtained. Both vagus nerves were simulta-
neously stimulated at 1-min intervals (2 Hz, 0.2 ms, 2.5–30 V, 44
pulses per train). The function of autoreceptors is frequency de-
pendent. Stimulation of M
 
2
 
Rs by endogenous acetylcholine is
greatest at high frequencies of stimulation. Therefore, the ability
of exogenous agonists to inhibit vagally induced bronchocon-
striction via stimulation of M
 
2
 
Rs is more readily apparent at low
frequencies of stimulation (5). Thus, the studies with the agonist
pilocarpine were carried out at 2 Hz. The voltage was chosen at
the beginning of each experiment (within a range of 2.5–30.0 V;
mean 9.11 
 
6
 
 0.92 V) to give an increase in 
 
P
 
pi
 
 of 
 
z
 
20 mmH
 
2
 
O
(21.4 
 
6
 
 0.75 mmH
 
2O). Cumulative doses of pilocarpine (1–100
mg?kg21) were administered intravenously, and the effect on
vagally induced bronchoconstriction was measured. 30–100
Figure 2. Pretreatment with AbIL5 before viral infection did not protect the ability of pilocarpine to inhibit vagally induced bronchoconstriction in
nonsensitized guinea pigs (A). Pilocarpine (1–100 mg?kg21 intravenous) inhibited vagally induced bronchoconstriction in control animals (open squares,
n 5 8), but not in virus-infected animals (filled squares, n 5 7) or in virus-infected animals pretreated with AbIL5 before infection (filled triangles, n 5
5). In contrast, in sensitized guinea pigs, AbIL5 given before viral infection did protect the ability of pilocarpine to inhibit vagally induced bronchocon-
striction (B). Pilocarpine (1–100 mg?kg21 intravenous) inhibited vagally induced bronchoconstriction in sensitized control animals (open circles, n 5 7),
but not in sensitized virus-infected animals (filled circles, n 5 10). However, pilocarpine did inhibit vagally induced bronchoconstriction in sensitized virus-
infected animals pretreated with AbIL5 (filled diamonds, n 5 5, P 5 0.0006). The control and virus-infected data of Figs. A and B are the same as shown
in Fig. 1. Each point is the mean, with SEM shown by vertical bars.1468 Antigen Sensitization and Viral Infection: The Role of Eosinophils
mg?kg21 of pilocarpine produced a small, transient bronchocon-
striction. Therefore, the effect of these doses of pilocarpine on
vagally induced bronchoconstriction was measured after the Ppi
had returned to baseline. At the end of each experiment, heparin
(2,000 U) was given intravenously in both the sensitized virus-
infected and nonsensitized virus-infected guinea pigs. After 15–20
min, the response to vagal stimulation was remeasured as above.
After the completion of each experiment, atropine (1 mg?kg21)
was given intravenously to confirm that bronchoconstrictions
were due to vagal stimulation. The results are expressed as a ratio
of bronchoconstriction in the presence of pilocarpine to the
bronchoconstriction in the absence of pilocarpine. Thus, a ratio
,1 would indicate that pilocarpine was inhibiting vagally in-
duced bronchoconstriction.
Studies of Postjunctional Muscarinic Receptor Function. The func-
tion of muscarinic receptors on airway smooth muscle was tested
in vagotomized guinea pigs by measuring bronchoconstriction in
response to increasing intravenous doses of acetylcholine (1–10
mg?kg21).
Bronchoalveolar Lavage. At the end of the experiment, bron-
choalveolar lavage was performed in situ via the tracheal cannula.
The lungs were lavaged with five aliquots of 10.0 ml PBS. The
recovered lavage fluid (40–45 ml) was centrifuged (350 g for 7
min). The cells were resuspended in 10 ml of deionized water to
remove any erythrocytes before an additional 40 ml of PBS was
added. Cells were centrifuged again, the supernatant was poured
off, and the cells were resuspended in 10 ml of PBS. Cells were
counted using a Neubauer Hemocytometer (Hausser Scientific
Co.). Aliquots of the cell suspension were cytospun onto glass
slides, stained with Diff-Quik® (Baxter Healthcare Corp.), and
counted to obtain differential cell counts.
Virus Isolation and Titration. Viral infection was confirmed in
all guinea pigs that were exposed to parainfluenza virus by infec-
tion of rhesus monkey kidney cells with aliquots of lung homo-
genate from each animal (see Fig. 12). After physiological studies
were completed, the guinea pig lungs were removed and stored
at 2708C. Frozen samples were thawed, weighed, and homoge-
nized in 2 ml PBS (Polytron™; Brinkmann). Virus was eluted
from the tissue homogenate by incubating at 348C for 1 h. The
suspensions were centrifuged at 450 g for 30 min, and the super-
natants were inoculated in serial 10-fold dilutions into fresh
rhesus monkey kidney cell monolayers. After 1 wk of incubation
at 348C, the monolayers were washed and the medium replaced
with a 0.5% suspension of guinea pig erythrocytes in Hank’s PBS.
After 1 h, the erythrocytes were washed off and the monolayers
were examined under an inverted phase–contrast microscope
(Olympus Corp.) for evidence of hemadsorption (sticking of
erythrocytes to the surface of cells because of expression of viral
hemagglutinin on these surfaces). Viral content was determined as
the amount of lung homogenate required to produce infection in
50% of rhesus monkey kidney monolayers (the TCID50), and is
expressed as TCID50/g lung wet wt. Only data from virus-
exposed guinea pigs with confirmed parainfluenza infection are
reported.
Drugs and Reagents. Acetylcholine, atropine, guanethidine,
heparin, OVA, pilocarpine, succinylcholine, and urethane were
Figure 3. Administration of AbMBP before viral infection of sensitized
animals protected the ability of pilocarpine to inhibit vagally induced
bronchoconstriction. Pilocarpine (1–100 mg?kg21 intravenous) inhibited
vagally induced bronchoconstriction in sensitized control animals (open
circles, n 5 7), but not in sensitized virus-infected animals (filled circles,
n 5 10), unless they were pretreated with AbMBP (filled diamonds, n 5
5; P 5 0.005). Each point is the mean, with SEM shown by vertical bars.
Figure 4. Pilocarpine (100 mg?kg21 intravenous) did not inhibit vagally
induced bronchoconstriction in virus-infected animals, whether they
were sensitized or not (black bars). Heparin (2,000 IU, intravenous) re-
stored pilocarpine’s ability to inhibit vagally induced bronchoconstriction
in virus-infected animals with prior sensitization (n 5 7, P 5 0.0001), but
not in nonsensitized virus-infected animals (n 5 5, gray bars). Each point
is the mean, with SEM shown by vertical bars.1469 Adamko et al.
purchased from Sigma Chemical Co. Purified rabbit AbMBP was
produced as described previously (13). Purified rat anti–mouse/
human AbIL5 (TRFK-5) was purchased from PharMingen. All
drugs were dissolved and diluted in 0.9% NaCl or PBS.
Statistics. All data are expressed as mean 6 SEM. Acetylcho-
line, frequency, and pilocarpine responses were analyzed using
two-way analyses of variance for repeated measures. Baseline
heart rates, blood pressures, Ppi, and changes in Ppi (before pilo-
carpine administration), histological measurements, and broncho-
alveolar lavage were analyzed using analysis of variance (Statview
4.5; Abacus Concepts, Inc.). A P value of 0.05 was considered
significant.
Results
Baseline Responses. There were no significant differ-
ences among the groups for baseline heart rate ([beats per
min] control, 261 6 3.7; virus-infected, 255 6 6.8; sensi-
tized, 261 6 5.7; sensitized virus-infected, 260 6 4.2;
virus-infected with AbIL5, 252.5 6 11.0; sensitized virus-
infected with AbIL5, 268 6 6.5; and sensitized virus-
infected with AbMBP, 270 6 6.6), systolic blood pressure
([mmHg) control, 51.2 6 1.7; virus-infected, 47.9 6 2.3;
sensitized, 51.3 6 2.2; sensitized virus-infected, 49.0 6 2.3;
virus-infected with AbIL5, 42.5 6 2.5; sensitized virus-
infected with AbIL5, 45.6 6 2.1; and sensitized virus-
infected with AbMBP, 47.1 6 1.5), diastolic blood pres-
sure ([mmHg] control, 29.4 6 1.5; virus-infected, 28.6 6
2.1; sensitized, 30.8 6 1.0; sensitized virus-infected, 29.0 6
1.3; virus-infected with AbIL5, 28.8 6 3.1; sensitized vi-
rus-infected with AbIL5, 27.8 6 2.2; and sensitized virus-
infected with AbMBP, 33.6 6 1.8), or animal weight ([kg]
control, 0.449 6 0.02; virus-infected, 0.516 6 0.03; sensi-
tized, 0.476 6 0.03; sensitized virus-infected, 0.434 6 0.02;
virus-infected with AbIL5, 0.424 6 0.02; sensitized virus-
infected with AbIL5, 0.461 6 0.04; and sensitized virus-
infected with AbMBP, 0.406 6 0.02).
A positive pressure of 70–220 mmH2O (mean 128 6
4.43 mmH2O) was needed to ventilate the animals. Sensiti-
zation of pathogen-free guinea pigs did not alter baseline
Ppi (90.7 6 4.1, n 5 14) compared with nonsensitized con-
trols (92.4 6 3.6, n 5 17). Regardless of sensitization, viral
infection increased baseline Ppi (sensitized 156.2 6 8.6, n 5
21; nonsensitized 151.0 6 8.5, n 5 10; P , 0.0001). The
increased baseline was not prevented by pretreatment with
AbIL5 (sensitized 143.3 6 9.6, n 5 9; nonsensitized 143.3 6
3.3, n 5 3), but was attenuated by treatment with AbMBP
in the sensitized virus-infected guinea pigs (112 6 9.6, n 5
7; P 5 0.0004).
Simultaneous electrical stimulation of both cut vagus
nerves at 2 Hz produced bronchoconstriction that was rap-
idly reversible upon cessation of stimulation. There were
no significant differences among the groups for the voltages
used (control, 5.8 6 1.4; virus-infected, 6.8 6 1.6; sensi-
tized, 10.7 6 3.4; sensitized virus-infected, 8.9 6 1.6; vi-
rus-infected with AbIL5, 8.9 6 2.0; sensitized virus-
infected with AbIL5, 5.8 6 1.4; and sensitized virus-infected
with AbMBP, 11.6 6 1.7) or the degree of bronchocon-
striction produced ([mmH2O] control, 20.9 6 0.5; virus-
infected, 19.8 6 1.1; sensitized, 25.0 6 2.0; sensitized vi-
rus-infected, 20.6 6 1.4; virus-infected with AbIL5, 19.2 6
2.9; sensitized virus-infected with AbIL5, 23.2 6 2.0; and
sensitized virus-infected with AbMBP, 19.2 6 2.6).
M2R Function. Pilocarpine inhibited vagally induced
bronchoconstriction in a dose-dependent manner in patho-
gen-free guinea pigs, demonstrating that there are func-
tional M2Rs on the parasympathetic nerves (Fig. 1). Sensi-
tization to OVA did not affect the ability of pilocarpine to
inhibit vagally induced bronchoconstriction. In virus-infected
animals, irrespective of sensitization, pilocarpine no longer
inhibited vagally induced bronchoconstriction (Fig. 1). This
demonstrates that the neuronal M2Rs were dysfunctional in
virus-infected guinea pigs.
Pretreatment with an AbIL5 did not prevent virus-induced
M2R dysfunction in nonsensitized guinea pigs (Fig. 2 A).
In contrast, pretreatment with AbIL5 did prevent virus-
induced M2R dysfunction in virus-infected guinea pigs sensi-
tized to OVA (Fig. 2 B). Likewise, pretreatment of sensi-
tized guinea pigs with AbMBP before viral infection also
protected the function of the neuronal M2Rs (Fig. 3).
Figure 5. Simultaneous electrical stimulation of both cut vagus nerves
(2.0–25 Hz, 10.0 V, 0.1 ms, 5 s) produced frequency-dependent bron-
choconstriction measured as an increase in Ppi. Viral infection significantly
potentiated vagally induced bronchoconstriction in both sensitized (filled
circles, n 5 5) and nonsensitized (filled squares, n 5 6) animals compared
with their respective controls (open circles, n 5 6; and open squares, n 5
8;  P  , 0.0001). Results are expressed as the mean increase in Ppi
(mmH2O). Each point is the mean, with SEM shown by vertical bars.1470 Antigen Sensitization and Viral Infection: The Role of Eosinophils
Heparin was administered after the maximal dose of
pilocarpine had been given. Heparin did not inhibit vagally
induced bronchoconstriction in the nonsensitized virus-
infected guinea pigs (Fig. 4). However, in sensitized virus-
infected guinea pigs, heparin did significantly inhibit vagally
induced bronchoconstriction.
Vagal Hyperreactivity in Sensitized and Nonsensitized Virus-
infected Animals. Simultaneous electrical stimulation of both
cut vagus nerves (1–25 Hz) caused frequency-dependent
bronchoconstriction. There was no difference between va-
gally induced bronchoconstriction in the uninfected sensi-
tized and nonsensitized guinea pigs (Fig. 5). In contrast,
after viral infection, vagally induced bronchoconstriction in
both sensitized and nonsensitized animals was significantly
greater than in their respective controls. This difference
was not apparent at lower frequencies of stimulation, but
became greater with increasing frequencies. Vagally induced
bronchoconstriction was not significantly different between
the sensitized and nonsensitized virus-infected groups.
Pretreatment with AbIL5 did not prevent virus-induced
vagal hyperreactivity in the nonsensitized guinea pigs (Fig.
6 A). In contrast, pretreatment with AbIL5 did prevent vi-
rus-induced vagal hyperreactivity in guinea pigs sensitized
to OVA (Fig. 6 B).
Pretreatment of the sensitized guinea pigs with AbMBP
before viral infection prevented virus-induced vagal hyper-
reactivity in the sensitized guinea pigs (Fig. 7). Likewise,
administration of heparin 30 min before testing vagal re-
sponses reversed virus-induced hyperreactivity to stimula-
tion of the vagus nerves in sensitized animals (Fig. 8).
Smooth Muscle Responsiveness in Sensitized and Nonsensi-
tized Virus-infected Animals. In vagotomized guinea pigs,
intravenous acetylcholine (2–10 mg?kg21) caused dose-depen-
dent bronchoconstriction. Acetylcholine-induced broncho-
constriction was not affected by sensitization, viral infection
(Fig. 9), or by any of the treatments (data not shown).
Effect of Sensitization and Virus Infection on Inflammatory
Cells Recovered in Lung Lavage. The total number of cells
recovered by lung lavage at the end of each experiment
was increased by viral infection regardless of whether the
animals were sensitized (Fig. 10). This increase was com-
prised of macrophages and neutrophils. Lymphocyte num-
bers were not significantly affected by either sensitization or
viral infection.
Sensitization significantly increased the number of eosin-
ophils recovered in the lavage fluid (white and gray bars;
Fig. 10). This increase with sensitization was not further
potentiated by viral infection (compare gray with hatched
Figure 6. Pretreatment of nonsensitized animals with AbIL5 did not prevent virus-induced vagal hyperreactivity (A). Vagally induced bronchoconstriction
in both nonsensitized virus-infected animals (filled squares, n 5 6) and nonsensitized virus-infected animals pretreated with AbIL5 (filled triangles, n 5 5)
remained greater than in nonsensitized control animals (open squares, n 5 8). In contrast, pretreatment of sensitized animals with AbIL5 did prevent virus-
induced vagal hyperreactivity in sensitized animals (B). Vagally induced bronchoconstriction in sensitized virus-infected animals (filled circles, n 5 5) was
greater than in sensitized control animals (open circles, n 5 6). Vagally induced bronchoconstriction in sensitized virus-infected animals pretreated with
AbIL5 (filled diamonds, n 5 5) was significantly decreased (P 5 0.004) to become similar to sensitized controls. Results are expressed as the mean increase in
Ppi (mmH2O). Virus-infected and control data are the same as shown in Fig. 5. Each point is the mean, with SEM shown by vertical bars.1471 Adamko et al.
bars). Viral infection did not increase the number of eosin-
ophils recovered in the lavage fluid in nonsensitized guinea
pigs (compare white with black bars).
Treatment with AbIL5 not did not change leukocyte
numbers in the lavage fluid of nonsensitized virus-infected
guinea pigs (Fig. 11 A.) In contrast, the total number of in-
flammatory cells in the sensitized virus-infected animals was
decreased by AbIL5 (Fig. 11 B). This decrease was due to a
significant decrease in eosinophils. Pretreatment with Ab-
MBP caused a small but statistically significant decrease in
the number of eosinophils recovered from the airways (Fig.
11 B). Neither AbIL5 nor AbMBP significantly altered the
numbers of lymphocytes recovered in the lavage fluid.
Effect of Sensitization on Viral Immunity. Infectious virus
was quantified in all guinea pigs that were exposed to
parainfluenza virus (Fig. 12). Viral content of the lungs was
significantly decreased in sensitized guinea pigs compared
with nonsensitized virus-infected guinea pigs. Pretreatment
with AbIL5 did not alter viral content of nonsensitized vi-
rus-infected guinea pigs. In contrast, there was a significant
increase in the viral content of AbIL5-treated, sensitized
virus-infected animals. Sensitized virus-infected animals
treated with AbMBP did not have any significant change in
the viral content. It is important to note that these results
were collected from all of the infected animals, but the ac-
tual titer measurements were performed on separate days
over a 4-mo period.
Discussion
The experiments described in this paper were designed
to test whether the mechanism of M2R dysfunction and as-
sociated airway hyperreactivity in virus-infected guinea
pigs differs between sensitized and nonsensitized animals.
In control guinea pigs, the muscarinic agonist pilocarpine
inhibited vagally induced bronchoconstriction in a dose-
dependent manner, confirming that neuronal M2Rs were
functioning to inhibit release of acetylcholine (5). Similarly,
pilocarpine also inhibited vagally induced bronchoconstric-
tion in the guinea pigs sensitized to OVA, confirming that
sensitization alone does not inhibit neuronal M2R function
(14). Likewise, sensitization does not induce vagal hyperre-
activity, since vagally induced bronchoconstriction was also
similar between sensitized and nonsensitized guinea pigs.
Figure 7. Pretreatment with AbMBP prevented virus-induced vagal
hyperreactivity in sensitized animals. Vagally induced bronchoconstric-
tion in sensitized virus-infected animals (filled circles, n 5 5) was greater
than in sensitized control animals (open circles, n 5 6). Vagally induced
bronchoconstriction in sensitized virus-infected animals pretreated with
AbMBP (filled diamonds, n 5 5) was significantly decreased (P 5 0.02)
to become similar to sensitized control animals. Results are expressed as
the mean increase in Ppi (mmH2O). Each point is the mean, with SEM
shown by vertical bars.
Figure 8. Heparin reversed virus-induced vagal hyperreactivity in sen-
sitized animals. Vagally induced bronchoconstriction in sensitized virus-
infected animals (filled circles, n  5 5) was significantly higher (P  ,
0.0001) than in sensitized control animals (open circles, n 5 6). Vagally
induced bronchoconstriction in sensitized virus-infected animals given
heparin (filled diamonds, n 5 5) was significantly decreased (P 5 0.0004)
to become similar to sensitized control animals. Virus-infected and con-
trol data are the same as shown in Fig. 5. Results are expressed as the
mean increase in Ppi (mmH2O). Each point is the mean, with SEM
shown by vertical bars.1472 Antigen Sensitization and Viral Infection: The Role of Eosinophils
In contrast, viral infection of both the sensitized and
nonsensitized guinea pigs caused loss of M2R function,
since pilocarpine no longer inhibited vagally induced bron-
choconstriction (Fig. 1). Viral infection also induced hy-
perreactivity in both the sensitized and nonsensitized
guinea pigs, since vagal nerve stimulation was potentiated
in both compared with their respective noninfected con-
trols (Fig. 5). The degree of vagal hyperreactivity was simi-
lar in the sensitized and nonsensitized virus-infected ani-
mals. This virus-induced hyperreactivity was mediated by
the parasympathetic nerves and not by a change in the re-
sponsiveness of airway smooth muscle, since bronchocon-
striction induced by intravenous acetylcholine was not dif-
ferent among the groups (Fig. 9). Thus, viral infection
causes loss of M2R function and vagal hyperreactivity, re-
gardless of sensitization status.
In antigen-challenged guinea pigs, hyperreactivity to
electrical stimulation of the vagus nerves as well as to intra-
venous histamine is mediated entirely by loss of neuronal
M2R function (15). We have demonstrated that broncho-
constriction in response to stimulation of the vagus nerves
is potentiated by viral infection in both sensitized and non-
sensitized guinea pigs. Since the responsiveness of airway
smooth muscle is not changed by viral infection or by sen-
sitization, virus-induced hyperreactivity to vagal nerve
stimulation results from increased release of acetylcholine
due to loss of neuronal M2R function.
Eosinophils, through release of MBP, mediate loss of
M2R function in antigen-challenged guinea pigs (10). In
contrast, we have shown that virus-induced M2R dysfunc-
tion and vagal hyperreactivity in nonsensitized guinea pigs
are not mediated by eosinophils. Depletion of eosinophils
with AbIL5 did not prevent virus-induced M2R dysfunc-
tion or vagal hyperreactivity (Figs. 2 A and 6 A). Further-
more, heparin, which binds and neutralizes eosinophil
MBP, did not reverse virus-induced M2R dysfunction or
vagal hyperreactivity (Fig. 4). Thus, virus-induced loss of
M2R function and hyperreactivity in nonsensitized guinea
pigs is not mediated by eosinophils.
In contrast, virus-induced loss of M2R dysfunction and
vagal hyperreactivity in sensitized guinea pigs is mediated
by eosinophils, and specifically via eosinophil MBP. Deple-
tion of eosinophils in sensitized, virus-infected guinea pigs
(Fig. 10 B) prevented M2R dysfunction, and also prevented
vagal hyperreactivity (Figs. 2 B and 6 B). Removing posi-
tively charged proteins with heparin both acutely restored
Figure 9. Intravenous injection of acetylcholine (1–10 mg/kg) pro-
duced dose-dependent bronchoconstriction, measured as an increase in
Ppi. Acetylcholine dose–response measurements in nonsensitized controls
(open squares, n 5 7), sensitized controls (open circles, n 5 5), nonsensi-
tized virus-infected (filled squares, n 5 7), and sensitized virus-infected
guinea pigs (filled circles, n 5 8) were not significantly different. Each
point is the mean, with SEM shown by vertical bars.
Figure 10. Airway leukocyte populations were measured in broncho-
alveolar lavage. There was a significant increase (P 5 0.0001) in the total
inflammatory cell number after viral infection of both nonsensitized
(black bar, n 5 10) and sensitized (hatched bar, n 5 16) animals compared
with their respective controls (white and gray bars, n 5 9–11). This in-
crease consisted of macrophages and neutrophils. Regardless of viral in-
fection, there was a significant increase in the number of eosinophils in
sensitized animals (gray bar, P 5 0.0295; and hatched bar, P 5 0.0004).
Data are expressed as the means of total cells recovered by lavage. Each
point is the mean, with SEM shown by vertical bars.1473 Adamko et al.
M2R function and reversed vagal hyperreactivity in the
sensitized virus-infected guinea pigs (Figs. 4 and 8). The
role of MBP was confirmed, since treatment with AbMBP
prevented both M2R dysfunction and vagal hyperreactivity
in the sensitized virus-infected guinea pigs (Figs. 3 and 7).
Thus, by sensitizing guinea pigs before viral infection, the
mechanism of virus-induced M2R dysfunction and vagal
hyperreactivity was switched to be clearly dependent on
eosinophils and eosinophil MBP.
Traditionally, eosinophils are not prominent in the re-
sponse of nonasthmatics to viruses. Airway viral infections
cause a neutrophil and mononuclear cell influx into the air-
ways (16). Typically, viral clearance has been attributed to
T cell release of IFN-g and TNF-a, and to direct killing by
CD81 cells and NK cells (17). A CD41 T lymphocyte re-
sponse may also contribute to viral clearance, and here
again it is production of INF-g by T cells that appears to be
beneficial (18).
Under some circumstances, viral infections do cause air-
way eosinophilia. Children who wheeze with respiratory
syncytial virus (RSV) infection have both increased eosino-
phils and eosinophil cationic protein (ECP) in their airways
(19). With viral infections other than RSV, eosinophilia is
seen in atopic individuals. During naturally acquired viral
infection, children with asthma have large increases in eosin-
ophil MBP regulated on activation, normal T cell ex-
pressed and secreted (RANTES), and macrophage-inhibi-
tory protein 1a in their nasal secretions (20). After
intranasal infection with rhinovirus, biopsies of the lower
airways of individuals with asthma contain increased eosin-
ophils that persist even into convalescence (21). In patients
with asthma, the presence of eosinophils and MBP in their
airways during periods of exacerbations has been well es-
tablished (22). However, the pathogenesis and role of this
eosinophilia in hyperresponsiveness have been unclear,
considering that many of these exacerbations are triggered
by viral infection (1, 23).
In mice, viral infection can induce airway eosinophilia
by production of IL-5 by T lymphocytes (24, 25). It has
been shown that, although under normal circumstances
CD81 T lymphocytes produce IFN-g in response to viral
infections, in an allergic milieu these CD81 cells respond to
viral infection by producing IL-5 (12). Studies by Coyle
et al. (12) used a transgenic mouse model in which the
CD81 T lymphocytes expressed the receptor for a particu-
lar viral glycoprotein. When these mice inhaled this glyco-
protein, there was increased IFN-g and an influx of neu-
trophils and mononuclear cells into the lung lavage.
However, if the mice were first sensitized to a nonviral an-
tigen, OVA, the response to inhaled viral glycoprotein was
Figure 11. Airway leukocyte populations were measured in bronchoalveolar lavage after pretreatment with AbIL5 and AbMBP. In nonsensitized
virus-infected animals (black bars, n 5 10), pretreatment with AbIL5 (gray bars, n 5 5) did not change any of the leukocyte numbers (A). In contrast,
pretreatment of sensitized virus-infected animals with AbIL5 (gray bars, n 5 8) significantly decreased the number of eosinophils compared with sensitized
virus-infected alone (black bars; n 5 16, P , 0.0001) (B). Pretreatment of sensitized virus-infected animals with AbMBP (dark gray bars, n 5 7) caused a
slight but statistically significantly decrease in eosinophil numbers compared with sensitized virus-infected animals alone (black bars; n 5 16, P 5 0.04).
In both AbIL5- and AbMBP-pretreated animals, neutrophil cell numbers were unaltered. Total leukocyte numbers were significantly decreased in sensi-
tized virus-infected animals treated with AbIL5 (light gray bar) compared with sensitized virus-infected animals alone (black bar, P 5 0.0025). Data are
expressed as the means of total cells recovered by lavage. Each point is the mean, with SEM shown by vertical bars.1474 Antigen Sensitization and Viral Infection: The Role of Eosinophils
production of IL-5 and an influx of eosinophils. These in-
vestigators demonstrated that exposure of the transgenic
CD81 T lymphocytes to IL-4 changed their in vitro re-
sponse to the viral glycoprotein from IFN-g to IL-5. Thus,
it was postulated that in an “atopic” animal (i.e., one that
had been sensitized), the production of IL-4 conditions the
CD81 T lymphocytes so that their response to viral infec-
tion is to produce IL-5 and to promote pulmonary eosino-
philia.
In vivo and in vitro experiments have investigated the
specific interactions between eosinophils and viruses. Viral
infection of epithelial cells causes release of the chemokines
for eosinophil migration such as RANTES, monocyte
chemotactic protein 1, and macrophage inhibitory protein
1a (26, 27). Eosinophils also respond directly to RSV in-
fection (28). After infection with rhinovirus, eosinophils
have been shown to activate T cells by acting as APCs (29).
This demonstrates that eosinophils are being recruited and
activated by viral infections. The possible mechanism of vi-
rus-induced eosinophil activation and granulation has been
studied by Olszewska-Pazdrak et al. (30). Incubation of
eosinophils with RSV-infected epithelial cells increases ex-
pression of the adhesion molecule CD18 on the eosino-
phils. Upregulation of Mac-1 (CD11b/CD18) is critical to
eosinophil activation (31), allowing the eosinophils to in-
teract with infected respiratory epithelium and to release
ECP. The increased expression of CD18 also allows virus-
specific T cells to bind and activate eosinophils.
An unexpected finding was an IL-5– and eosinophil-
dependent antiviral effect in sensitized animals. Sensitization
before viral infection decreased the viral content of the
lungs by .80% (Fig. 11). AbIL5 pretreatment reversed the
effect of sensitization, increasing viral titers in the lungs of
sensitized virus-infected guinea pigs. In contrast, pretreat-
ment with AbIL5 in the nonsensitized virus-infected guinea
pigs had no effect on viral titers. This suggests that in addi-
tion to changing the mechanism of M2R dysfunction, sen-
sitization before viral infection has also changed the guinea
pig’s ability to clear virus. The increased eosinophils in sen-
sitized virus-infected animals were associated with de-
creased viral titer, whereas depleting eosinophils with AbIL5
was associated with increased viral titers. Although treatment
with AbMBP did cause a small but significant decrease in
eosinophil number, this decrease was much less than the
decrease associated with AbIL5 treatment (Fig. 10 B). Treat-
ment with AbMBP did not alter the viral content in the
lungs of sensitized virus-infected guinea pigs. Therefore,
the mechanism of the eosinophil’s apparent ability to en-
hance viral clearance does not involve eosinophil MBP, as
AbMBP treatment did not interfere with the ability of sen-
sitization to lower viral titers.
Although the activation of eosinophils by viral infection
has been shown, the possible direct antiviral role of eosino-
phils is less clear. ECP and eosinophil-derived neurotoxin
are both RNases (32) that can inhibit replication of RNA
viruses such as parainfluenza (33). Domachowske et al.
have demonstrated, in vitro, that eosinophils can directly
inhibit both RSV and parainfluenza virus infectivity (34).
They found that the mechanism of eosinophil antiviral ac-
tivity is through the RNase activity of eosinophil-derived
neurotoxin and ECP (35).
Another possible antiviral mechanism for eosinophils
may be through release of nitric oxide (NO), which is an
effective inhibitor of viral replication (36). While the viru-
cidal effects of eosinophils through production of NO have
not been investigated, eosinophils do use NO production
to kill parasites (37). NO production by eosinophils is in-
creased in sensitized guinea pigs (38). Exhaled NO levels
are increased in patients with asthma (39), and specifically
during virus-induced asthma attacks (40).
In addition to the possible antiviral effects of eosinophils,
other effectors in the Th2 pathway may also play a role in
viral clearance. In mice, IL-5 plays an important role in
mucosal immunity through the induction of plasma cell re-
lease of IgA (41). IL-5 may also play a role in systemic im-
munity through B cell growth and differentiation (42) and
induction of receptors for IL-2 (43), although studies in
human B cells have yielded conflicting results (44, 45).
IL-5 may also act to stimulate differentiation of cytotoxic T
lymphocytes (46). Although viral clearance is primarily de-
pendent on cytotoxic T cell responses, antibody responses
can also affect viral clearance (47). Therefore, it is possible
Figure 12. Viral titers from the lungs of all virus-exposed guinea pigs
were quantified. Sensitized virus-infected guinea pigs (white bar, n 5 19)
had a significant decrease in viral titer compared with nonsensitized virus-
infected guinea pigs (black bar, n 5 11, P 5 0.04). Pretreatment with
AbIL5 had no effect on nonsensitized virus-infected guinea pigs (hatched
bar, n 5 3), but caused a significant increase in recovered viral titers in
sensitized virus-infected animals (light gray bar, n 5 11, P , 0.0001).
Sensitized virus-infected guinea pigs treated with AbMBP (dark gray bar,
n 5 7) continued to have decreased viral titers compared with untreated,
sensitized virus-infected animals.1475 Adamko et al.
that the effect of AbIL5 on the viral titers recovered in our
sensitized virus-infected guinea pigs could also have oc-
curred through disruption of a noneosinophil inflammatory
pathway.
We have demonstrated that virus-induced loss of M2R
function in nonsensitized virus-infected guinea pigs is not
mediated by eosinophils. In contrast, by sensitizing guinea
pigs to a nonviral protein before viral infection, we have
switched the response to subsequent viral infection to de-
pend on eosinophils. We have demonstrated that in sensi-
tized animals, virus-induced hyperreactivity results from
activation of eosinophils, release of MBP, and inhibition of
neuronal M2R function.
M2Rs are present in humans (48), and loss of M2R func-
tion is associated with airway hyperreactivity in patients
with asthma (49, 50). Although the neuronal M2Rs are
functional in humans with stable asthma, their function is
lost during naturally acquired viral infection (51).
Asthma attacks are often precipitated by viral infection and
are characterized by an eosinophilic airway inflammatory re-
sponse, yet viral infection is not traditionally associated with
eosinophilia. We have shown that sensitizing guinea pigs to a
nonviral protein before viral infection switches the inflam-
matory response to viral infection to include eosinophils.
Many asthmatics are atopic and have increased eosinophils in
their airways even during periods of quiescence (52). Our
data suggest that eosinophils play an important role in the re-
sponses of patients with atopic asthma to viral infection. This
altered mechanism may be important in understanding the
role viruses play in triggering asthma exacerbations. In addi-
tion, under these circumstances, eosinophils may play an ad-
ditional role in viral clearance.
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